$2B

Bayer to Acquire Vividion for ~$2B

Shots: Vividion to receive $1.5B up front & $500M milestone while Bayer to get full rights to Vividion’s discovery platform which consists of chemoproteomic screening technology, a data portal, and a chemistry library. The transaction is expected to close in Q3’21 The acquisition will strengthen Bayer’s drug discovery capabilities & expand it into new modalities. …

Bayer to Acquire Vividion for ~$2B Read More »

Servier to Acquire Agios’ Oncology Business for ~$2B

Shots: Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through the loss of exclusivity and 15% royalties on sales of vorasidenib in the US from first commercial sale through the loss of exclusivity The acquisition …

Servier to Acquire Agios’ Oncology Business for ~$2B Read More »